Liquid Trace™
Detects Actionable Mutations in Plasma
Analyzes over 1,500 genes (DNA & RNA).
Identifies key gene amplifications, including HER2, FGFR, PI3KCA, and RAS.
Identifies key fusions, MRD, HRR, HPV/EBV.
Gene expression & alternative splicing.
Chromosomal abnormalities including gene amplification.
Identifies targeted therapy options, and immune therapy options.
Treatment monitoring.
Clinical trial matching.
CellSearch®
Circulating Tumor Cells
Isolates and counts cancer cells.
Measures HER2 low, PDL1 or ER.
FDA cleared for patients with breast, colon, prostate, gallbladder/biliary tract, and anal cancer.
Measures a patients response to therapy over time through serial testing.
CellSearch® is now available for patients with Multiple Myeloma and Melanoma to quantitatively monitor residual disease.
Insurance: The assay is covered by insurance and can be applied to patients with cancer.
Turn-around Time: Liquid Trace™ - 7 business days, CellSearch® - 7 business days.
Contact Us for Information or to Order:
For more information, email us at support@proteanbiodx.com, or call us at +1 (754) 242 9682
